Pfizer announced plans to sell a plant in India that was slated to be shuttered. But another Pfizer facility in Ireland that was once on the chopping block has not only been taken off the list of facilities no longer needed but is adding several dozen jobs.
Pfizer recently gave up plans to try to turn its cholesterol fighter Lipitor into an OTC drug, but sales of the drug have remained surprisingly strong for a product that went off patent nearly four years ago. That has led Pfizer to add jobs at a factory in Ireland that two years ago teetered on the brink of closure.
Statins have been linked with cardiovascular problems as well as amnesia and mental decline. But neurological side effects are not turning up as frequently in postmarketing safety data. And muscle-related side effects, which are also commonly linked to the drugs, show up more often in three Merck products than in the rest of the class.
Millions of Americans take statins to help control their cholesterol and try to stay heart healthy. You just can't count on them to handle that on their own, Pfizer has found. And so the maker of Lipitor, the most successful statin of them all, has given up on its efforts to move the drug to an over-the-counter treatment.
Almost two years after announcing it would close a Lipitor-producing plant in Cork County, Ireland, Pfizer has officially said it will keep the plant operational. It turns out there is enough demand around the world for its off-patent cholesterol drug for the plant to remain open "for the foreseeable future."
It's official: Demand for the off-patent drug Lipitor has inspired Pfizer to keep an Irish plant it had slated for closure.
SINGAPORE--An Australia Federal Court justice dismissed a case brought by the nation's consumer watchdog agency, saying it failed to prove Pfizer Australia violated the law by muscling out the competition for its Lipitor (atorvastatin) anti-cholesterol drug.
A Pfizer plant in Ireland that was slated to close last year is still running strong, as sales of blockbuster cholesterol drug Lipitor remain vibrant in some parts of the world three years after losing its U.S. patent.
Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting blockbuster Lipitor.
Sales of Lipitor, the best-selling drug of all time, may be waning, but litigation over the cholesterol fighter is growing--a lot.